Indaptus Therapeutics filings document a clinical-stage biotechnology issuer developing Decoy20 and related immunotherapy programs for cancer and viral infections. The company’s regulatory record includes material-event reports, proxy statements, capital-structure disclosures, and governance filings tied to its Nasdaq-listed common stock.
Key filing subjects include convertible preferred stock, warrants, warrant repricing agreements, voting agreements, unregistered securities, shareholder meeting proposals, and changes in control. The filings also cover board and officer appointments or resignations, compensatory arrangements, operating and financial results, and material agreements that affect the company’s financing, governance, and public-company structure.
Indaptus Therapeutics, Inc. (INDP) entered into an Amended and Restated At the Market Offering Agreement with H.C. Wainwright & Co., LLC on August 28, 2026. The agreement allows Indaptus to issue and sell shares of its common stock from time to time through or to Wainwright under an at-the-market equity program.
The program covers up to $100,000,000 in aggregate gross sales price of common stock, in addition to any shares previously sold under the prior 2022 agreement. Sales are made under the company’s effective Form S-3 shelf registration statement and an August 31, 2026 ATM prospectus supplement. Wainwright acts as sales agent and may also act as principal under separate terms agreements, earning a 3.0% fee on gross sales when acting as agent. Neither party is obligated to sell or purchase shares, and the offering can be suspended at any time.
Indaptus Therapeutics, Inc. (INDP) has established an amended at-the-market equity program to sell up to $100,000,000 of common stock from time to time through or to H.C. Wainwright & Co. under an August 28, 2026 offering agreement, replacing a 2022 ATM. Wainwright will act as sales agent and/or principal and receive a 3.0% commission on gross proceeds. At August 26, 2026, common shares outstanding were 133,242,324, and an illustrative sale of 87,719,298 shares at $1.14 would raise the full capacity.
Net tangible book value at June 30, 2026 was $13.3 million ($0.10 per share); assuming full ATM usage at $1.14, pro forma net tangible book value would be $110.3 million or $0.50 per share, implying dilution of $0.64 to new investors. The company highlights significant risks, including a going-concern explanatory paragraph from its auditor and the absence of any active clinical development programs pending additional financing and strategic review of its Decoy20 immunotherapy platform.
Indaptus Therapeutics, Inc. (INDP) filed a prospectus to register the resale of up to 58,895,000 shares of common stock held by existing investors. The company is not selling any shares and will receive no proceeds; all sale proceeds go to the selling stockholders.
The registered shares comprise 20,000,000 shares issued in a June 2026 private placement and 38,895,000 shares issued upon conversion of Series AAA preferred stock tied to a December 2025 investment and a March 2026 share transfer that resulted in a change of control. These shares equal about 44.2% of the 133,242,324 shares outstanding.
Indaptus is a clinical-stage biotechnology company centered on its Decoy20 immunotherapy platform, but it has no active clinical development programs and has discontinued enrollment in all Decoy20 studies while it evaluates strategic alternatives. Its auditor’s report referenced substantial doubt about the company’s ability to continue as a going concern, and recent ownership and board changes have concentrated control among new stockholders.
Indaptus Therapeutics, Inc. is registering for resale up to 58,895,000 shares of Common Stock, all to be sold by existing holders. The company is not selling shares in this transaction and will receive no proceeds from these resales.
The registered shares comprise 20,000,000 shares sold in a June 17, 2026 private placement for $12.0 million and 38,895,000 shares issued upon conversion of 259,300 Series AAA Preferred originally sold to David Lazar and later transferred under a March 2026 secondary sale agreement. As of this prospectus, these 58,895,000 shares equal 44.2% of the 133,242,324 shares outstanding, creating a sizable potential resale overhang.
Indaptus, a clinical-stage immunotherapy company, has halted enrollment in all Decoy20 trials, has no active clinical programs, and is evaluating strategic alternatives, including transactions or new research initiatives. Recent financing history includes multiple 2024–2026 equity rounds, a now-terminated $20.0 million equity line, a 1-for-28 reverse stock split, and a December 2025 preferred investment that led to a March 2026 change of control. The most recent audit report includes a going-concern explanatory paragraph.
Indaptus Therapeutics, Inc. is a clinical-stage biotech that has halted further clinical development of its Decoy20 program and is actively evaluating strategic alternatives, including a potential investment in or acquisition of an operating business. During the quarter it also initiated a neurological and sleep research collaboration in China and engaged new scientific consulting focused on data-driven health and neurophysiological signals.
For the three months ended June 30, 2026, net loss narrowed to $1.8 million from $5.2 million a year earlier, driven by an 83% reduction in research and development expenses and a 37% decline in general and administrative costs as clinical activities and headcount were scaled back. For the six-month period, net loss fell to $4.3 million from $9.8 million.
Liquidity improved through a December 2025 preferred stock investment that converted into 111,000,000 common shares and a June 17, 2026 private placement of 20,000,000 common shares at $0.60 per share, generating approximately $12.0 million in gross proceeds. As of June 30, 2026, cash and cash equivalents were $7.6 million and certificates of deposit totaled $4.0 million. Management believes these resources fund operations through the second quarter of 2027, yet discloses substantial doubt about the company’s ability to continue as a going concern given ongoing losses, strategic uncertainty, and future financing needs.
Indaptus Therapeutics, Inc. reported substantially lower operating expenses and losses for the quarter and six months ended June 30, 2026, while strengthening its balance sheet with a $12.0 million private placement. Management is reviewing its Decoy immunotherapy platform, broader research activities and strategic alternatives, including potential investments or business combinations.
Research and development expenses fell 83% to about $0.4 million in the quarter, and general and administrative expenses declined to about $1.4 million. Quarterly net loss narrowed to approximately $1.8 million from $5.2 million a year earlier. As of June 30, 2026, cash, cash equivalents and short-term investments totaled about $11.6 million, and total assets were $12.0 million against $0.6 million of liabilities.
Stockholders approved all items at the 2026 annual meeting, including electing three Class II directors, ratifying Haskell & White LLP as auditor, and approving the 2026 Equity Incentive Plan. The company notes risks including substantial doubt about its ability to continue as a going concern and the need for additional capital to pursue its strategy.
Indaptus Therapeutics, Inc. is asking stockholders to vote at its 2026 annual meeting, to be held virtually on August 10, 2026. Holders of 113,242,324 shares of common stock outstanding as of June 12, 2026 may vote.
Stockholders will elect three Class II directors to serve until the 2029 meeting, ratify Haskell & White LLP as independent auditor for 2026, and approve a new 2026 Equity Incentive Plan. The plan initially reserves 13,324,232 shares, with an automatic annual increase of 5% of shares outstanding from 2027 through 2031, while shutting off future grants and the evergreen feature under the 2021 plan.
The proxy also details 2025 executive pay, including total compensation of $2,197,171 for Co‑CEO Jeffrey A. Meckler, $1,953,870 for COO Walt A. Linscott and $1,691,286 for Chief Scientific Officer Michael J. Newman, as well as cash-and-stock payments under 2025 modification agreements tied to a recapitalization.
Sino Lion Ventures Limited and Chenhao Xu have filed Amendment No. 2 to their Schedule 13D on Indaptus Therapeutics, Inc. They report beneficial ownership of 38,895,000 shares of common stock, representing 29.19% of the company, held with shared voting and dispositive power.
The amendment explains that their percentage ownership fell by more than 1% solely because Indaptus increased its outstanding common shares in a private placement on June 17, 2026, reaching 133,242,324 shares outstanding as of June 24, 2026. The reporting persons did not buy or sell any Indaptus shares for this change to occur.
Sino Lion Ventures originally acquired its position through a Securities Purchase Agreement dated March 19, 2026, funding the purchase of Series AA and Series AAA Preferred Stock with $3,998,898.44 in working capital, which converted into common stock at the March 23, 2026 closing.